Effects of berberine hydrochloride tablets combined with compound glutamine on intestinal mucosal barrier function in patients with ulcerative colitis

doi:10.11958/20231293

Abstract

Abstract:

Objective To investigate the effect of berberine hydrochloride tablets combined with compound glutamine in treating ulcerative colitis (UC). Methods One hundred and two patients with UC admitted to our hospital were collected and grouped into two groups according to the random number table. Fifty-one patients in the control group were given conventional treatment+compound glutamine, and 51 patients in the experimental group were given berberine hydrochloride tablets based on the control group. Both groups were treated for 8 weeks. The efficacy, modified Mayo score, intestinal mucosal barrier function, soluble late glycation end product receptor (sRAGE), interleukin-17 (IL-17), IL-6 and incidence of untoward reactions were compared between the two groups. Results The total effective rate of the experimental group was higher than that of the control group (92.2% vs. 76.5%, P<0.05). After treatment, scores of defecation frequency, blood in stool, endoscopic findings, physician's overall evaluation, diamine oxidase (DAO), D-lactic acid, endotoxin, sRAGE, IL-17 and IL-6 were lower in both groups than those before treatment (P<0.05), and the research group was lower than the control group (P<0.05). There was no significant difference in the total incidence of untoward reactions between the experimental group and the control group (P>0.05). Conclusion Berberine hydrochloride tablets combined with compound glutamine are effective in treating UC, which can reduce the activity of UC, improve the intestinal mucosal barrier function, regulate serum sRAGE, IL-17 and IL-6 levels, without increasing adverse reactions.

Key words: Berberine, glutamine, colitis, ulcerative, intestinal mucosal barrier

CLC Number:

R574.621，R969

Figures/Tables 6

References 32

[1]	中国中西医结合学会. 溃疡性结肠炎中西医结合诊疗专家共识[J]. 中国中西医结合杂志, 2023, 43(1):5-11.
	Chinese Association of Integrative Medicine. Ulcerative colitis combine traditional Chinese and western medicine diagnosis and treatment expert consensus[J]. Chin J Integr Trad West Med Dig, 2023, 43(1):5-11. doi:10.7661/j.cjim.20221027.215.
[2]	KOBAYASHI T, SIEGMUND B, LE BERRE C, et al. Ulcerative colitis[J]. Nat Rev Dis Primers, 2020, 6(1):74. doi:10.1038/s41572-020-0205-x.
[3]	LE BERRE C, ANANTHAKRISHNAN A N, DANESE S, et al. Ulcerative colitis and crohn's disease have similar burden and goals for treatment[J]. Clin Gastroenterol Hepatol, 2020, 18(1):14-23. doi:10.1016/j.cgh.2019.07.005.
[4]	李宝瑜, 李彦龙, 田旭东. 中药防治溃疡性结肠炎相关机制的研究进展[J]. 中医药导报, 2023, 29(5):212-216.
	LI B Y, LI Y L, TIAN X D. Research progress on the mechanism of traditional Chinese medicine in prevention and treatment of ulcerative colitis[J]. Guiding J Tradit Chin Med Pharm, 2023, 29(5):212-216. doi:10.13862/j.cn43-1446/r.2023.05.047.
[5]	ROSELLI M, FINAMORE A. Use of synbiotics for ulcerative colitis treatment[J]. Curr Clin Pharmacol, 2020, 15(3):174-182. doi:10.2174/1574884715666191226120322.
[6]	刘坤, 徐菁, 马竹芳, 等. 复方谷氨酰胺联合美沙拉秦对溃疡性结肠炎患者炎症状况及凝血功能的影响[J]. 河北医药, 2023, 45(11):1710-1712.
	LIU K, XU J, MA Z F, et al. Effect of compound glutamine combined with mesalazine on inflammatory status and coagulation function in patients with ulcerative colitis[J]. Hebei Med J, 2023, 45(11):1710-1712. doi:10.3969/j.issn.1002-7386.2023.11.026.
[7]	季双双, 刘子号, 王梦媛, 等. 盐酸小檗碱辅助治疗溃疡性结肠炎及对炎症因子影响的Meta分析[J]. 海南医学院学报, 2022, 28(19):1493-1501.
	JI S S, LIU Z H, WANG M Y, et al. A meta-analysis of berberine hydrochloride in adjuvant treatment of ulcerative colitis and its influence on inflammatory factors[J]. J Hainan Med Univ, 2022, 28(19):1493-1501. doi:10.13210/j.cnki.jhmu.20210514.002.
[8]	崔文娟, 蔡杰超, 巩颍, 等. 盐酸小檗碱片联合柳氮磺吡啶治疗溃疡性结肠炎的临床研究[J]. 现代药物与临床, 2021, 36(1):85-89.
	CUI W J, CAI J C, GONG Y, et al. Clinical study on berberine hydrochloride tablets combined with sulfasalazine in treatment of ulcerative colitis[J]. Drugs & Clinic, 2021, 36(1):85-89. doi:10.7501/j.issn.1674-5515.2021.01.017.
[9]	熊亚立, 陈诚, 胡光明, 等. 小檗碱通过促进巨噬细胞M2极化缓解溃疡性结肠炎[J]. 西北药学杂志, 2021, 36(3):414-419.
	XIONG Y L, CHEN C, HU G M, et al. Berberine alleviates ulcerative colitis by promoting M2 polarization of macrophages[J]. Northwest Pharma J, 2021, 36(3):414-419. doi:10.3969/j.issn.1004-2407.2021.03.015.
[10]	RUTGEERTS P, SANDBORN W J, FEAGAN B G, et al. Infliximab for induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2005, 353(23):2462-2476. doi:10.1056/NEJMoa050516.
[11]	中国中西医结合学会消化系统疾病专业委员会. 溃疡性结肠炎中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2018, 26(2):105-111,120.
	Digestive Diseases Committee of Chinese Association of Integrated Traditional and Western Medicine. Consensus on the diagnosis and treatment of ulcerative colitis with integrated traditional Chinese and western medicine(2017)[J]. Chin J Integr Trad West Med Dig, 2018, 26(2):105-111,120. doi:10.3969/j.issn.1671-038X.2018.02.01.
[12]	陈林. 复方谷氨酰胺联合美沙拉秦治疗溃疡性结肠炎的效果及其抗炎机制[J]. 临床与病理杂志, 2023, 43(3):461-468.
	CHEN L. Efficacy of compound glutamine combined with mesalazine in the treatment of ulcerative colitis and its anti-inflammation mechanism[J]. J Pathol Clin Res, 2023, 43(3):461-468. doi:10.11817/j.issn.2095-6959.2023.221842.
[13]	王佳俊, 王建, 李勇, 等. 基于细胞信号通路探讨小檗碱治疗溃疡性结肠炎研究进展[J]. 中国中药杂志, 2021, 46(1):33-40.
	WANG J J, WANG J, LI Y, et al. Research progress of effect of berberine in treatment of ulcerative colitis based on cell signaling pathway[J]. China J Chin Materia Med, 2021, 46(1):33-40. doi:10.19540/j.cnki.cjcmm.20201002.601.
[14]	朱烟林, 康敏, 彭时成, 等. 复方谷氨酰胺联合双歧杆菌三联活菌胶囊对腹泻型肠易激综合征患者肠黏膜屏障功能、胃肠激素和血清5-HT、SPY水平的影响[J]. 现代生物医学进展, 2022, 22(2):352-355.
	ZHU Y L, KANG M, PENG S C, et al. Effects of compound glutamine combined with bifidobacterium triple viable capsule on intestinal mucosal barrier function,gastrointestinal hormone and serum 5-HT and spy levels in patients with diarrhea irritable bowel syndrome[J]. Progr Mod Biomed, 2022, 22(2):352-355. doi:10.13241/j.cnki.pmb.2022.02.030.
[15]	唐煌尧, 杨亭, 赵华, 等. 小檗碱对炎症性肠病肠道屏障的影响及其信号通路[J]. 动物营养学报, 2020, 32(2):523-529.
	TANG H Y, YANG T, ZHAO H, et al. Effects of berberine on intestinal barrier of inflammatory bowel disease and its signaling pathways[J]. Chin J Animal Nutrit, 2020, 32(2):523-529. doi:10.3969/j.issn.1006-267x.2020.02.006.
[16]	蔡兴炎, 李枝锦, 林力森, 等. 愈肠止痢方对活动期溃疡性结肠炎患者疾病活动度及肠黏膜屏障功能的影响[J]. 现代中西医结合杂志, 2021, 30(25):2816-2819.
	CAI X Y, LI Z J, LIN L S, et al. Effect of Yuchang Zhili Formula on disease activity and intestinal mucosal barrier function in patients with active ulcerative colitis[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2021, 30(25):2816-2819. doi:10.3969/j.issn.1008-8849.2021.25.019.
[17]	徐春霞, 李荣军, 杨小丽, 等. 从肺论治以荆芥连翘方结合针刺鬼眼穴治疗溃疡性结肠炎的临床观察[J]. 湖南中医药大学学报, 2023, 43(2):338-342.
	XU C X, LI R J, YANG X L, et al. Treatment of ulcerative colitis with Jingjie Lianqiao Decoction in combination with acupuncture at Guiyan (LU 11 and SP 1) from the viewpoint of "treating lung primarily"[J]. J Tradit Chin Med Univ Hunan, 2023, 43(2):338-342. doi:10.3969/j.issn.1674-070X.2023.02.026.
[18]	HEIZATI M, LI N, SHAO L, et al. Does increased serum d-lactate mean subclinical hyperpermeability of intestinal barrier in middle-aged nonobese males with OSA?[J]. Medicine(Baltimore), 2017, 96(49):e9144. doi:10.1097/MD.0000000000009144.
[19]	周海娟, 陈刚, 李枝锦. 清热愈疡汤对大肠湿热型溃疡性结肠炎患者炎性因子、内毒素及肠黏膜屏障的影响[J]. 广州中医药大学学报, 2023, 40(3):563-569.
	ZHOU H J, CHEN G, LI Z J. Effects of qingre yuyang decoction on inf lammator factors,endotoxin and intestinal mucosal barrier in patients with ulcerative colitis of large intestine damp-heat type[J]. J Guangzhou Univ Trad Chin Med, 2023, 40(3):563-569. doi:10.13359/j.cnki.gzxbtcm.2023.03.006.
[20]	李金敏, 贾海燕, 王俊杰, 等. 谷氨酰胺对溃疡性结肠炎小鼠结肠损伤的影响[J]. 中国应用生理学杂志, 2009, 25(2):268-272.
	LI J M, JIA H Y, WANG J J, et al. Effects of glutamine on the colon of mice subjected to colitis gravis[J]. Chin J Appl Physiol, 2009, 25(2):268-272. doi:10.13459/j.cnki.cjap.2009.02.030.
[21]	YAN S, HUI Y, LI J, et al. Glutamine relieves oxidative stress through PI3K/Akt signaling pathway in DSS-induced ulcerative colitis mice[J]. Iran J Basic Med Sci, 2020, 23(9):1124-1129. doi:10.22038/ijbms.2020.39815.9436.
[22]	甘金刚, 樊海南, 张志强. 盐酸小檗碱对溃疡性结肠炎患者肠道菌群及免疫状态的影响[J]. 中国中西医结合消化杂志, 2020, 28(12):949-953.
	GAN J G, FAN H N, ZHANG Z Q. Effects of chlorhexidine hydrochloride on intestinal flora and immune status in patients with ulcerative colitis[J]. Chin J Integr Trad West Med Dig, 2020, 28(12):949-953. doi:10.3969/j.issn.1671-038X.2020.12.10.
[23]	KAENKUMCHORN T, WAHBEH G. Ulcerative colitis:making the diagnosis[J]. Gastroenterol Clin North Am, 2020, 49(4):655-669. doi:10.1016/j.gtc.2020.07.001.
[24]	李为慧, 吴正祥, 陶科明, 等. RAGE、sRAGE在溃疡性结肠炎中的表达及临床意义[J]. 安徽医科大学学报, 2013, 48(4):394-397.
	LI W H, WU Z X, TAO K M, et al. Expression of RAGE,sRAGE in ulcerative colitis and clinical significance[J]. Acta Univ Med Anhui, 2013, 48(4):394-397. doi:10.19405/j.cnki.issn1000-1492.2013.04.017.
[25]	BRAMHALL M, RICH K, CHAKRABORTY A, et al. Differential expression of soluble receptor for advanced glycation end-products in mice susceptible or resistant to chronic colitis[J]. Inflamm Bowel Dis, 2020, 26(3):360-368. doi:10.1093/ibd/izz311.
[26]	FAUNY M, MOULIN D, D'AMICO F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers[J]. Ann Rheum Dis, 2020, 79(9):1132-1138. doi:10.1136/annrheumdis-2020-217927.
[27]	ANSARI M N, REHMAN N U, KARIM A, et al. Role of oxidative stress and inflammatory cytokines (TNF-α and IL-6) in acetic acid-induced ulcerative colitis in rats:ameliorated by otostegia fruticosa[J]. Life (Basel), 2021, 11(3):195. doi:10.3390/life11030195.
[28]	叶青, 刘东升, 王兰霞, 等. 茯苓化学成分、药理作用及质量控制研究进展[J]. 中医药信息, 2023, 40(2):75-79.
	YE Q, LIU D S, WANG L X, et al. Research progress on chemical constituents,pharmacological effects and quality control of poria cocos[J]. Infor Trad Chin Med, 2023, 40(2):75-79. doi:10.19656/j.cnki.1002-2406.20230214.
[29]	肖先, 李春燕, 刘晓龙, 等. 甘草的主要化学成分及药理作用研究进展[J]. 新乡医学院学报, 2023, 40(3):280-285.
	XIAO X, LI C Y, LIU X L, et al. Research progress of main chemical constituents and pharmacological effects of glycyrrhizae radix et rhizoma[J]. J Xinxiang Med Univ, 2023, 40(3):280-285. doi:10.7683/xxyxyxb.2023.03.016.
[30]	陈志国, 魏海梁, 闫曙光, 等. 谷氨酰胺通过PI3K/AKT/NF-κB信号通路抑制炎症反应治疗溃疡性结肠炎[J]. 营养学报, 2022, 44(6):577-585.
	CHEN Z G, WEI H L, YAN S G, et al. Glutamine inhibits inflammatory respone in mice with ulcerative colitis induced by dss through PI3K/AKT/NF-κB signaling pathway[J]. Acta Nutr Sinica, 2022, 44(6):577-585. doi:10.3969/j.issn.0512-7955.2022.06.011.
[31]	DE OLIVEIRA SANTOS R, DA SILVA CARDOSO G, DA COSTA LIMA L, et al. L-glutamine and physical exercise prevent intestinal inflammation and oxidative stress without improving gastric dysmotility in rats with ulcerative colitis[J]. Inflammation, 2021, 44(2):617-632. doi:10.1007/s10753-020-01361-3.
[32]	何涛宏, 陈敏, 郝亮亮, 等. 盐酸小檗碱对溃疡性结肠炎大鼠炎症的影响[J]. 中国临床药理学杂志, 2020, 36(21):3461-3464.
	HE T H, CHEN M, HAO L L, et al. Effect of berberine hydrochloride on the inflammation of ulcerative colitis rats[J]. Chin J Clin Pharmacol, 2020, 36(21):3461-3464. doi:10.13699/j.cnki.1001-6821.2020.21.016.

组别	男性		年龄/岁		病程/年
对照组	30（58.8）		39.63±6.28		3.42±0.56
试验组	26（51.0）		40.11±6.64		3.23±0.74
χ2或t	0.634		0.375		1.462
组别				病变范围
组别		直肠		左半结肠		全结肠
对照组		12（23.5）		29（56.9）		10（19.6）
试验组		14（27.5）		25（49.0）		12（23.5）
χ2或t		0.632

组别	男性		年龄/岁		病程/年
对照组	30（58.8）		39.63±6.28		3.42±0.56
试验组	26（51.0）		40.11±6.64		3.23±0.74
χ2或t	0.634		0.375		1.462
组别				病变范围
组别		直肠		左半结肠		全结肠
对照组		12（23.5）		29（56.9）		10（19.6）
试验组		14（27.5）		25（49.0）		12（23.5）
χ2或t		0.632

组别	排便次数			便血			内镜发现			医师总体评价
组别	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	2.10±0.30	1.61±0.49	5.717^＊＊	2.06±0.37	1.57±0.50	5.435^＊＊	1.96±0.34	1.51±0.50	5.585^＊＊	1.88±0.33	1.63±0.49	3.250^＊＊
试验组	2.06±0.31	1.27±0.45	11.146^＊＊	1.98±0.37	1.24±0.43	8.947^＊＊	1.92±0.39	1.20±0.40	8.598^＊＊	1.92±0.34	1.41±0.50	6.704^＊＊
t	0.648	3.563^＊＊		1.066	3.615^＊＊		0.537	3.475^＊＊		0.598	2.211^＊

组别	排便次数			便血			内镜发现			医师总体评价
组别	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	2.10±0.30	1.61±0.49	5.717^＊＊	2.06±0.37	1.57±0.50	5.435^＊＊	1.96±0.34	1.51±0.50	5.585^＊＊	1.88±0.33	1.63±0.49	3.250^＊＊
试验组	2.06±0.31	1.27±0.45	11.146^＊＊	1.98±0.37	1.24±0.43	8.947^＊＊	1.92±0.39	1.20±0.40	8.598^＊＊	1.92±0.34	1.41±0.50	6.704^＊＊
t	0.648	3.563^＊＊		1.066	3.615^＊＊		0.537	3.475^＊＊		0.598	2.211^＊

组别	DAO/（U/L）			D-乳酸/（mg/L）			内毒素/（U/L）
组别	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	18.73±2.88	15.58±2.73	5.669^＊＊	35.14±4.62	28.28±4.16	7.880^＊＊	16.37±2.78	13.19±2.53	6.042^＊＊
试验组	18.47±2.95	13.76±2.31	8.977^＊＊	34.27±4.45	24.35±3.52	12.486^＊＊	16.56±2.91	10.58±2.17	11.765^＊＊
t	0.450	3.634^＊＊		0.969	5.150^＊＊		0.337	5.592^＊＊